Karen P retweeted
The webinar will feature our management team, @HTawbi_MDPhD Dr. Hussein A. Tawbi (MD Anderson) and @Andr3_M Dr. André Mansinho (START Lisbon), a principal investigator in ABILITY-1.
Updated data will be presented by Dr. @PAscierto Paolo Ascierto at #SITC26 on Nov 7.
News release: ir.medicenna.com/news-releas…
Niko's story is an exciting & important addition to the patient stories of those who received NVG-291 in $NGEN P2 trial. P3 trial is now recruiting SCI patients in 2 centers, will soon be recruiting in 21 more. Looking forward to many other nerve injury responses e.g. stroke, MS!
Niko was left quadriplegic after a car accident. He lost hand, triceps, bowel, bladder and sexual function, facial movement, and blood pressure and temperature regulation.
After taking $NGEN’s NVG-291 peptide for 12 weeks, he reportedly regained much of that function.
Bio/Acc. Disclaimer: I don't have a position on $NGEN.
7
723
Karen P retweeted
I was a white girl at a majority black, inner city school. Here’s what the education debate gets wrong
Learn more about nerve repair at nervgen.com.
Research and development day:
edge.media-server.com/mmc/p/…
Interviews with 4 patients are seen at
CONNECT SCI Participant:
nervgen.com/presentations/?_…
Today, we announced that the first participant has been dosed in RESTORE, our Phase 3 registrational study evaluating NVG-291 in chronic spinal cord injury.
Read more:
nervgen.com/nervgen-announce…
#SCI #SpinalCordInjury
Karen P retweeted
Measles was kept down for decades, but Trump's Republicans decided to bring it back. Unacceptable. #GOPWarOnHealthcare
Karen P retweeted
Congratulations to our 2026 Emerging Company of the Year - Biotech: NervGen, which is being recognized for an important milestone in advancing new treatment options for spinal cord injury.
Award sponsor: AbCellera
Video production credit: bioflim MEDIA
youtu.be/sLqabjBHTLU
$NGEN This is great news for those who have spinal cord injury! Their P2 small trial demonstrated that nerve regeneration is real and possible. The 10 patients who received the drug all confirmed safety and showed various degrees of improvement with hand and other abilities.
🚨 BIG NEWS for the spinal cord injury community!
NervGen is finally recruiting for its P3 clinical trial of NVG-291! 🙌🙏🏼
If you or someone you know is living with a spinal cord injury, visit ClinicalTrials.gov to learn more and see if you may qualify.
#SCI #SpinalCordInjury #NVG291 #NervGen $NGEN
8
439
More than 15 million people worldwide live with SCI. Behind every number is a person with individual experiences, priorities and goals.
This #SCIAwarenessMonth, join the conversation and register for the Patient-Focused Drug Development meeting on SCI: scipfdd.org
Karen P retweeted
With ALL my contacts, I’ve been PRIVATELY trying to reach President Trump with ONE request:
🇺🇸 SIGN AN EXECUTIVE ORDER FOR A DOLLY PARTON U.S. POSTAGE STAMP — with proceeds supporting CHILDHOOD LITERACY and the IMAGINATION LIBRARY! 📚❤️
NO ONE will put my call through…
Apparently, they’ve already heard about me! 😂
Mr. President — CALL ME! ☎️🇺🇸
#DollyStamp #DollyParton #ImaginationLibrary #USPS @realDonaldTrump @Pontifex @AndyBeshearKY @RepAndyBarr @SenMcConnell @DollyParton @dollyslibrary
Karen P retweeted
Stacye was left completely paralysed after an accident
Then she took a peptide called NVG-291
A few weeks ago she was able to walk a few blocks with a walker
FDA peptide meeting this week. Watch this before everyone else does
Consensus is there's no treatment that restores function after spinal cord injury.
These are people from the latest $NGEN trial.
Some got NVG-291, a peptide that blocks the CSPG/PTPσ brake on axon regrowth. Some got placebo.
I'm not telling you what it means. They will.
Karen P retweeted
STOP comparing Afghan women in burqas and Iranian women under compulsory hijab with Christian nuns.
This really isn’t complicated.
A nun chooses to become a nun. Her vow applies to her. She doesn’t take the vow and suddenly every woman in Italy has to cover her hair.
And if she removes her veil, the morality police don’t show up to beat her, arrest her, or throw her in prison.
That’s the difference.
In Iran and Afghanistan, the rules don’t care whether you’re religious, secular, Muslim, atheist, or just want to be left alone. You’re a woman? Congratulations. The authorities have a dress code for you.
And please stop pointing at little girls in hijab and calling it “choice.” Some of these children can’t even read yet. They’re old enough to choose a religious obligation for life, but apparently not old enough to choose what they want for lunch?
Here’s the test nobody seems to want to take:
What happens when a woman says NO?
If the answer is guns and bullets, prison, beatings, losing your education, or being erased from public life, congratulations, you’ve discovered the difference between choice and coercion.
And if you still think the Taliban model is somehow “liberating,” try it yourself. Cover up. Obey. Let religious authorities decide how you dress, where you go, whether you work, and when you’re allowed to speak. Then explain to Afghan women how empowered you feel.
Is this really that difficult to understand?
#LetUsTalk
Karen P retweeted
Replying to @adamfeuerstein
In rare disease setting PUL data is excellent, just ask The Lancet. Better yet ask the kids who have been getting drug for years, and their families. Highly approvable by FDA. PDUFA extended to 11/20. Conditional approval granted. Not every day that price target raised by 800%.
Karen P retweeted
Replying to @C5625797576187
The Trump administration has fought for logic in decision making yet old dogma still holds strong.
Karen P retweeted
Brilliant post Adcom Analysis! Deramiocel must be approved!@Capricor $CAPR @ParentProjectMD @SenRonJohnson @RobertKennedyJr @realDonaldTrump @houmanhemmati
@Elijahjstacy
$CAPR
HOPE 3: Deramiocel outperformed placebo in rank-based scoring. (drug has treatment EFT)
all DMD Trials: fail to show 1-year absolute effect.
HOPE 2 / OLE: 5-year data proves long-term efficacy.
Supported by general DMD natural progression studies.
Deramiocel works.
Karen P retweeted
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial - The Lancet thelancet.com/journals/lance…
$CAPR #Deramiocel #DMD @US_FDA what more can we ask for please
Karen P retweeted
1/ $CAPR has been selling off on talk that the company might have been inadvertently unblinded before updating the HOPE-3 statistical plan. That story is getting more attention than it deserves. Here’s the actual situation.
2/ Capricor was very deliberate about this. They told investors back in 2025 that they would send the revised SAP to the FDA first, wait for feedback, and only unblind after that. That’s exactly what they did.
3/ Linda Marban has been clear on this. The company was not unblinded to the results before the SAP was submitted and approved. The changes were discussed with the FDA and they had their blessing. Everything was documented and shared with the agency.
4/ She even said this is probably just something the FDA wants to go over at the AdCom for transparency. Not because there’s an actual issue.
5/ On top of that, the change in how they analyzed the PUL 2.0 data (moving toward relative change and percent slowing instead of just absolute mean change) actually makes the results easier to understand. DMD patients start at very different levels of function, so showing how much the drug slowed decline compared to placebo (54% in this case) is more meaningful than raw point differences alone.
6/ PUL 2.0 itself is a solid, well-established tool. It was developed by an international group of clinicians and researchers, including Anna Mayhew and Eugenio Mercuri, and refined with better statistical methods to track upper limb function in DMD.
7/ The July 29 AdCom is there to look at these exact kinds of questions. The FDA will lay out any concerns they have, Capricor will walk through the timeline and procedures, and the panel will discuss it openly. That’s how these meetings work.
8/ At the end of the day HOPE-3 hit its main goal on PUL 2.0 and the key heart function measure, with results that line up with what they saw before. The noise around unblinding is mostly speculation that doesn’t line up with how the company actually ran the trial.
Karen P retweeted
Fantastic news. Video of 4 people in $NGEN NervGen drug trial for spinal cord paralysis treatment NVG-291. All on the drug had amazing results. One regained use of her hand in just 3 weeks on the drug. All can mostly walk now. The drug has kept working after they stopped using it; it allows nerves to regrow, and the nerves keep growing and connecting even months after treatment. If anyone can get this to RFK or anyone high up in the FDA, please do. It is very safe, should have been approved 6 months ago. antoniolinares.substack.com/…






























